Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.53 |
| ▸ | RPS6KA1 | Q15418 | 14/20 | 0.53 |
| ▸ | AKT2 | P31751 | 6/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | RPS6KA5 | O75582 | 5/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303916 | 0.92 | AKT1 (0.52) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL4301439 | 0.87 | AKT1 (0.73) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL5011017 | 0.83 | SLC2A1 (0.55) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL4298408 | 0.80 | SLC2A1 (0.52) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL21350454 | 0.80 | AKT1 (0.73) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL4293734 | 0.79 | AKT1 (0.73) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL4293083 | 0.78 | AKT1 (0.51) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL13702485 | 0.77 | AKT1 (0.54) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL4295261 | 0.77 | AKT1 (0.61) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL4298401 | 0.77 | SLC2A1 (0.50) | AKT1ROCK1RPS6KA1AKT2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885ROCK1 478/4885RPS6KA1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.